Prospective, multi-centric, open label, two arm, parallel group, active control, randomized, comparative clinical study to evaluate efficacy and safety of R-TPR-017 / MabThera in patients with Follicular B-Cell Non-Hodgkins Lymphoma.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Sep 2016
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Sponsors Reliance Life Sciences
- 12 Sep 2016 Status changed from recruiting to active, no longer recruiting.
- 21 Jan 2012 New trial record